Advestra acted as Swiss legal counsel to Novartis, which successfully placed notes in the aggregate principal amount of USD 3.7 billion in four tranches of USD 1 billion 3.800%
Advestra advised eMolecules and Avista Healthcare Partners (of which eMolecules is a porfolio company), on the acquisition of all shares in Synple Chem. The acquisition strategically expands eMolecules’ product and service portfolio to
Neo Medical, a Swiss technology company specializing in spine surgery, has announced the successful completion of a strategic equity investment, including the conversion of existing shareholder loans. The financing round was led by Gyrus Capital,
Sandoz, a global leader in the generics and biosimilars markets successfully placed EUR 600 million senior guaranteed Eurobonds listed on the SIX Swiss Exchange, advised by Advestra. The bonds are issued by Sandoz Finance B.V.
Kellerhals Carrard advised Broadview Ventures and Panakes Partners in leading the EUR 44 million Series B financing round of CorFlow Therapeutics, advised by Walder Wyss. This round also includes participation from Merieux Equity Partners, Laerdal Million
Advestra advised Galderma on its inaugural bonds in the aggregate principal amount of CHF 500 million. The payment date of the bonds is September 27, 2024. The bonds will be listed on the SIX Swiss Exchange and are
Walder Wyss advised the shareholders of Saiba Animal Health in the sale of all shares to the biopharmaceutical company Boehringer Ingelheim. With the acquisition, Boehringer Ingelheim strengthens its animal health research and development (R&
Vischer advised Haya Therapeutics, a Swiss biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics, which announced a multi-year agreement with Eli Lilly and Company to apply Haya’s advanced RNA-guided regulatory genome platform to
Walder Wyss advised SkyCell on its USD 116 million Series D financing round. It embarked on a USD 57 million equity investment by M&G Investments in October 2023 and has now been completed with further investments
Vischer advised Mininavident, located in Liestal, a developer and manufacturer of the world’s smallest dynamic navigation system for dental implant placement, which was acquired by the Straumann Group, a global leader in tooth replacement,
